Another Strong Quarter For AbbVie, But How Long Will Good Times Last?

30 Jul 2016

• By Joseph Haas

With continued strong growth for Humira, AbbVie doubles down on confidence to protect the franchise with IP strategy. Imbruvica and Viekira Pak show growth, although the latter is flourishing only ex-US.

The narrative on AbbVie Inc. has been unchanging – it relies too much on top-seller Humira, is clearly behind Gilead in hepatitis C and its cancer portfolio and pipeline, while promising, aren't threatening to overtake competitors like Bristol-Myers Squibb Co. or Merck & Co. Inc. To that familiar litany, AbbVie continued its recent success July 29, reporting a sixth consecutive quarter of double-digit sales growth, paced by continued increasing sales of Humira.

The Chicago-area pharma brought in $6.432bn in global net revenue during the second quarter of 2016, up 18.0% year-over-year, with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

11 Aug 2025

• By Alexandra Shimmings

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

06 Aug 2025

• By Kevin Grogan

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

31 Jul 2025

• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

31 Jul 2025

• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

Boehringer Scores First Approval For Targeted Oral Drug In HER2-Mutant NSCLC

11 Aug 2025

• By Alaric DeArment

The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.